One of the main advantages of ixazomib is its oral administration, which improves patient convenience and compliance compared to intravenous therapies. The drug has demonstrated efficacy in prolonging progression-free survival in multiple myeloma patients. Additionally, as part of combination therapy, it can enhance the effectiveness of treatment regimens and provide a feasible option for patients who have relapsed or are refractory to other treatments.
